EMEA-001084-PIP02-11

Key facts

Invented name
  • Exelon
  • Prometax
Active substance
rivastigmine
Therapeutic area
Neurology
Decision number
P/113/2011
PIP number
EMEA-001084-PIP02-11
Pharmaceutical form(s)
  • Capsule, hard
  • Oral solution
  • Transdermal patch
Condition(s) / indication(s)
Treatment of dementia
Route(s) of administration
  • Oral use
  • Transdermal use
Contact for public enquiries
Novartis Europharm Ltd

E-mail: paediatric.enquiries@novartis.com
Tel. +41 6132 41111  / +41 6132 46715

 

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating